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Abstract
Background: Electroconvulsive therapy (ECT) has been reported being a safe and effective treatment in schizophrenia. However, there are a limited number of 
studies assessing continuation ECT utilization in patients with schizophrenia giving partial response to pharmacological treatment. Objective: The aim of this 
study is to evaluate the effectiveness of continuation ECT in preventing relapse in patients with treatment-resistant schizophrenia. Methods: In this retrospective 
analysis, schizophrenia patients (n = 73) were defined in three groups such as patients who received only AP treatment (only AP), patients who received acute 
ECT only during hospitalization (aECT+AP), patients who received acute ECT and continuation ECT (a-cECT+AP). Three groups were compared according to 
positive and negative syndrome scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) scores. Results: As per comparison of only AP group, aECT+AP group 
and a+cECT+AP groups in terms of after discharge PANSS and after discharge BPRS scores for 1st month, 3rd month and 6th month; 3rd and 6th month’s PANSS 
scores of a+cECT+AP group were statistically significantly lower than other two groups. Discussion: Although this study suffers the limitations of retrospective 
medical chart analysis, results suggest that, in patients with a diagnosis of schizophrenia who have responded to an acute course of ECT, continuation ECT in 
combination with antipsychotics is more effective than antipsychotics alone in preventing relapse.
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Resumo
Contexto: A eletroconvulsoterapia (ECT) tem mostrado ser um tratamento seguro e eficaz para esquizofrenia. No entanto, o número de estudos que avaliam 
a utilização contínua de ECT em pacientes com esquizofrenia e a resposta parcial ao tratamento farmacológico é limitado. Objetivo: O objetivo deste estudo 
é avaliar a eficácia da ECT de continuação na prevenção de recaída em pacientes com esquizofrenia resistente ao tratamento. Métodos: Nesta análise retros-
pectiva, pacientes com esquizofrenia (n = 73) foram alocados em três grupos: pacientes que receberam apenas o tratamento AP (somente AP), pacientes que 
receberam um curso agudo de ECT durante a hospitalização (aECT+AP) e pacientes que receberam um curso agudo de ECT durante a hospitalização e ECT 
de continuação (a-cECT+AP). Esses três grupos foram comparados de acordo com a pontuação atribuída na Positive and Negative Syndrome Scale (PANSS) 
e na Brief Psychiatric Rating Scale (BPRS). Resultados: De acordo com a comparação dos grupos, somente em AP, aECT+AP e a+cECT+AP, em termos de 
PANSS e BPRS, após descarga no primeiro, terceiro e sexto mês, as pontuações na PANSS no terceiro e sexto mês no grupo a+cECT+AP foram estatística e 
significativamente menores do que nos outros dois grupos. Conclusões: Embora este estudo mostre limitações causadas pela análise retrospectiva de prontu-
ários, os resultados sugerem que a continuação da ECT em combinação com antipsicóticos é mais eficaz do que somente os antipsicóticos, na prevenção da 
recaída em pacientes com diagnóstico de esquizofrenia que responderam ao curso agudo de ECT.
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Introduction
Electroconvulsive therapy (ECT) is one of the oldest biological treat-
ment methods used in the field of modern psychiatry. This method 
based on the generation of generalized convulsions by stimulating 
the brain tissue with electrical current. ECT has been introduced into 
clinical use before the development of psychopharmacology at the 
end of the 1930s. Despite the avoidance and stigmatization of ECT 
caused by the negative reflection of some movies and novels, today, 
ECT is recognized as one of the most effective treatment options1. 
It is used in cases of severe depression and mania, and in catatonic 
patients who do not respond to other treatments or who require 
urgent solutions, many successful results were also obtained after 
ECT applications in many disorders other than those listed2.
The exact mechanism of ECT is unclear, but there is a wide range 
of theories regarding its effectiveness. Some of them are amnestic 
theory, the theory of the autonomic nervous system, neurohumoral 
theory, anticonvulsant theory and the theory of the neuroendocrine 
system3. According to these theories, ECT increases receptor sensi-
tivity in dopaminergic and noradrenergic pathways, and serotonin 
turnover; it also activates monoaminergic pathways extending 
from diencephalic centers to hypothalamus and limbic regions4. 
Elevation in plasma cortisol levels and prolactin secretion during 
ECT indicates an increase in hypothalamic activity and, an increase 
in neurotransmitter activity5,6. It is reported that ECT corrects the 
hemispheric dysfunction and provides synchronization between the 
left and right hemispheres7. According to the anticonvulsant theory, 
therapeutic effect depends on the brain’s finalization process of the 
seizure, but not directly on ECT-induced convulsive seizures. In other 
word, although ECT causes seizure, it shows anticonvulsant effect 
in the long-term. It was reported that seizure threshold elevation 
was associated with a favorable clinical response6,7. In Turkey, the 
frequency of ECT applications in inpatients is 14%-16%, and it is 
about 5%-12% in the USA and many Asian countries8-10. 
According to the clinical situation and the response, ECT is 
implemented two or three times a week and 5-12 sessions in total3. 
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In the first years of use, ECT has been applied without intravenous 
anesthetics and muscle relaxants; it caused fractures and perceived 
as a fearful traumatic experience. Today, ECT is applied with intra-
venous anesthetics and muscle relaxants11,12. Continuation ECT is 
applied after acute ECT at least for six months in order to prevent 
relapse; Maintenance ECT is applied after a successful ECT course 
within the first six months at regular intervals ranging from a week 
to a month in order to prevent recurrence; the ones applied after 
6 months are recommended to be called as “Preventive ECT”13,14. 
According to American Psychiatric Association, Maintenance 
ECT criteria: repetitive, episodic illness which respond to ECT; 
inability to tolerate maintenance drug treatment or ineffectiveness 
in preventing early exacerbations; being able to adapt to Mainte-
nance ECT15,16. ECT has been reported being a safe and effective 
treatment in schizophrenia the first acute attack, and in patients 
with catatonia and suicide risks17-19. However, there are a limited 
number of studies assessing continuation ECT utilization in patients 
with schizophrenia giving partial response to pharmacological 
treatment19-20. In one of these studies, patients with schizophrenia 
were compared by dividing into three groups, patients receiving 
both continuation ECT and flupenthixol, patients receiving con-
tinuation ECT alone, and patients receiving flupenthixol alone. In 
this study, group of patients receiving both continuation ECT and 
neuroleptics had a relapse rate significantly lower than the other 
two groups19. In another study, it has been reported that a patient 
with catatonic schizophrenia and tardive dyskinesia has benefited 
from continuation ECT21. The aim of this study is to evaluate the 
effectiveness of continuation ECT in preventing relapse in patients 
with treatment-resistant schizophrenia. 
Methods
Files of 255 patients who were diagnosed with schizophrenia ac-
cording to DSM IV-TR between January 2012 and March 2013 after 
psychiatric assessment in Uskudar University NP Istanbul Psychiatry 
Hospital and hospitalized, and followed-up as an outpatient after 
discharge were evaluated retrospectively. The study continued with 
73 patients with schizophrenia as patients using only a combination 
of 800-1400 mg/d chlorpromazine equivalent dose antipsychotic 
(AP) during their hospitalization and outpatient follow-up were 
included, and patients with comorbid psychiatric and neurological 
diagnoses and those with alcohol and substance abuse/dependence 
were excluded. These patients were defined in three groups such as 
patients who received only AP treatment (only AP), patients who 
received acute ECT only during hospitalization (aECT+AP), patients 
who received acute ECT and continuation ECT (a-cECT+AP). Only 
AP group, aECT+AP group, and a-cECT+AP group were compared 
according to positive and negative syndrome scale (PANSS) and Brief 
Psychiatric Rating Scale (BPRS) scores. Scales applied to patients at 
the baseline, at time of hospitalization were hospitalization-PANSS 
(H-PANSS) and hospitalization BPRS (H-BPRS); scales applied to 
patients during discharge were discharge PANSS (D-PANSS) and 
discharge BPRS (D-BPRS).
PANS and BPRS scores of three groups followed-up during 
six months after discharged were compared for the 1st month, 3rd 
month and 6th month. Continuation ECT was defined as ongoing 
ECT that was administered after completion of the course of three 
times a week acute ECT, beginning with the administration of ECT 
on a weekly or less frequent basis. All data on demographic and 
clinical characteristics were abstracted from all patients’ charts 
retrospectively.
ECT protocol
All ECT applications were short pulsed with continuous flow through 
MECTA-SPECTRUM brand ECT device brief pulse, square wave 
type, 500-800 mA (milliamps). All of the patients received bilateral 
bitemporal ECT application. For the formation of an effective con-
vulsion, 20-60 joule current with the energy level of 3-8 was applied. 
ECT induced seizure duration was monitored with electroencepha-
lography (EEG) (Thymatron System IV Somatics, IL, USA). ECT was 
applied three times in a week after 12-hour fasting and psychoactive 
medications were stopped 12 hours before ECT. Age-based method 
used as ECT stimulus dosing protocol22. This protocol was reviewed 
by the Uskudar University institutional review board and judged to 
be exempt from the requirement for written informed consent due 
to its retrospective design.
Statistical methods 
SPSS (Statistical Package for Social Sciences) for Windows 16.0 soft-
ware was used to analyze study data. Quantitative variables were ex-
pressed as mean ± standard deviation (SD) while qualitative variables 
were expressed as numbers and percentages. A normal distribution 
was found for quantitative variables by using the Shapiro-Wilk nor-
malcy test (p > 0.05). Comparison of the Only AP group, aECT+AP 
group, and a-cECT+AP group was the Pearson chi-square analysis. 
The three-way comparison of the Only AP group, aECT+AP group, 
and a-cECT+AP group for PANSS and BPRS scores was with the one-
way variance analysis (ANOVA) test and the two-way comparison 
with the Tukey method. The intragroup variables were tested with 
the Pearson Correlation Analysis. A p value < 0.05 was accepted as 
statistically significant.
Results 
The study included 26 only AP patients with schizophrenia, 28 
aECT+AP patients with schizophrenia, 19 a+cECT+AP patients with 
schizophrenia; a total of 73 patients with schizophrenia. The mean 
age of the only AP group was 31.92 ± 7.82 years, the mean age of 
the aECT+AP group was 31.82 ± 6.65 years, and the mean age of the 
a+cECT+AP group was 34.79 ± 9.80 years. There was no statistically 
significant difference in three groups in terms of socio-demographic 
characteristics (p ≥ 0.05), (Table 1).
aECT+AP group received 9.71 ± 2.17 ECT, a+cECT+AP group 
received 21.89 ± 9.80 ECT. According to the comparison of the 
three groups in terms of H-PANSS, D-PANSS, H-BPRS, D-BPRS 
scores, a+cECT+AP group’s H-BPRS, D-BPRS scores were statisti-
cally significantly higher than only AP group and aECT+AP group 
(p < 0.01). There were no differences between groups in terms of 
Table 1. Comparison of the only AP group, aECT+AP group and a+cECT+AP 
group in terms of socio-demographic characteristics
Only AP group
(n = 26)
aECT+AP 
group (n = 28)
a+cECT+AP 
group (n = 19)
p
Age (year) 
(Mean ± SD)
31.92 ± 7.82 31.82 ± 6.65 34.79 ± 9.80 0.39a
Gender (n, %)
Female 10 (38.5%) 13 (46.4%) 7 (36.8%) 0.76b
Male 16 (61.5%) 15 (53.6%) 12 (63.2%)
Marital status 
(n, %)
Married 11 (42.3%) 12 (42.9%) 11 (57.9%) 0.52b
Single 15 (57.7%) 16 (57.1%) 8 (42.1%)
Education 
(n, %)
Primary 
school
19 (73.1%) 21 (75.0%) 13 (68.4%) 0.88b
High 
school/+
7 (26.9%) 7 (25.0%) 6 (31.6%)
Occupation 
(n, %)
Working 4 (15.4%) 4 (42.6%) 3 (15.8%) 0.99b
Not working 22 (84.6%) 24 (85.7%) 16 (82.2%)
a: one-way variance analysis (ANOVA) test used; b: chi-square test used.
92 Gul IG, et al. / Rev Psiq Clín. 2014;41(4):90-4
Table 2. Comparison of only AP group, aECT+AP group and a+cECT+AP 
group in terms of numbers of ECT applied and H-PANSS, D-PANSS, H-BPRS, 
D-BPRS scores
Only AP group
(n = 26)
aECT+AP 
group (n = 28)
a+cECT+AP 
group (n = 19)
p
(Mean ± SD) (Mean ± SD) (Mean ± SD)
Number of ECTs 9.71 ± 2.17 21.89 ± 9.80 0.0001a
0.0001c
H-PANSS 107.12 ± 23.37 101.11 ± 22.90 110.00 ± 19.33 0.37a
0.58b
0.37c
0.90d
D-PANSS 56.35 ± 9.47 51.11 ± 10.14 51.53 ± 12.36 0.15a
0.17b
0.99c
0.29d
H-BPRS 45.35 ± 11.62 43.14 ± 15.85 60.32 ± 10.24 0.0001a*
0.81b
0.0001c*
0.001d*
D-BPRS 19.27 ± 6.83 16.46 ± 6.63 31.37 ± 11.18 0.0001a*
0.42b
0.0001c*
0.0001d*
*: statistically significant; a: between only AP group, aECT+AP group and a+cECT+AP groups; 
b: between only AP group, aECT+AP groups; c: between aECT+AP group and a+cECT+AP groups; 
d: between only AP group, and a+cECT+AP groups.
Table 3. Comparison of only AP group, aECT+AP group and a+cECT+AP 
group in terms of PANSS and BPRS scores for 1.month, 3.month and 6.month 
Only AP group
(n = 26)
aECT+AP 
group
(n = 28)
a+cECT+AP 
group
(n = 19)
p
(Mean ± SD) (Mean ± SD) (Mean ± SD)
1.month PANSS 54.81 ± 13.91 52.25 ± 10.83 51.16 ± 12.69 0.59a
0.73b
0.95c
0.60d
3.month PANSS 68.35 ± 25.94 62.25 ±24.17 42.26 ± 12.12 0.001a*
0.58b
0.01c*
0.001d*
6.month PANSS 73.50 ± 38.72 66.57 ± 37.46 33.37 ± 11.93 0.0001a
0.73b
0.004c*
0.0001d*
1.month BPRS 18.88 ± 8.84 19.96 ± 13.64 29.84 ± 10.85 0.004a*
0.94b
0.01c*
0.006d*
3.month BPRS 25.54 ± 13.90 25.54 ± 15.65 23.11 ± 9.94 0.80a
1.00b
0.82c
0.83d
6.month BPRS 32.46 ± 23.32 28.29 ± 23.26 16.58 ± 8.57 0.04a*
0.74b
0.11c
0.03d*
*: statistically significant; a: between only AP group, aECT+AP group and a+cECT+AP groups; 
b: between only AP group, aECT+AP groups; c: between aECT+AP group and a+cECT+AP groups; 
d: between only AP group, and a+cECT+AP groups.
Table 4. In aECT+AP group and a+cECT+AP group; correlation analysis 
between the numbers of ECT and PANSS and BPRS scores
Number of ECT Number of ECT 
(n = 47) (r) (n = 47) (p)
D-PANSS (-0.320) (0.03*)
D-BPRS (0.235) (0.11)
1.month PANSS (-0.219) (0.14)
3.month PANSS (-0.630) (0.0001*)
6.month PANSS (-0.655) (0.0001*)
1.month BPRS (0.231) (0.12)
3.month BPRS (-0.281) (0.05)
6.month BPRS (-0.464) (0.001*)
Pearson correlation tests were used; *: statistically significant; PANSS-D: Y- PANSS and T-PANSS 
rate of change; BPRS-D: Y-BPRS and T-BPRS rate of change.
ECT is applying protective ECT for 4-12 months after the comple-
tion of the ECT implementation in the acute phase. However, lack of 
prospective, randomized study concerning the validity of this method 
and the fact that patients has to undergo general anesthesia for 
months restricts the applicability23,24. According to the findings of this 
study performed with the aim to evaluate the efficacy of  continuation 
ECT on patients with schizophrenia who receive preventive phar-
macotherapy; Y-BPRS, T-BPRS scores of the a+cECT+AP group 
were significantly higher than both only AP group and aECT+AP 
group. There were no differences between groups in terms of other 
scales. Scores of BPRS which is used to assess severity and changes 
of psychotic and depressive symptoms in schizophrenia and other 
other scales (p ≥ 0.05) (Table 2). Although the a+cECT+AP group 
had slightly longer mean duration of disease (10.89 ± 7.31 years), 
the mean length of disease did not differ statistically significantly 
between groups (p = 0.16)
As per comparison of only AP group, aECT+AP group and 
a+cECT+AP groups in terms of after discharge PANSS and after 
discharge BPRS scores for 1st month, 3rd month and 6th month; 3rd 
and 6th month’s PANSS scores of a+cECT+AP group were statistically 
significantly lower than other two groups (p < 0.01). 1st month’s BPRS 
scores of a+cECT+AP group were statistically significantly higher 
than other two groups (p < 0.05). 6th month’s BPRS of a+cECT+AP 
group were statistically significantly lower than only AP group (p 
< 0.05). There were no significant differences between 1st month’s 
PANSS and 3rd month’s BPRS scores of the three groups (p > 0.05) 
(Table 3).
In aECT+AP group and a+cECT+AP group (n = 47); in cor-
relation analysis between numbers of ECT and PANSS and BPRS 
scores; rate of change of the number of ECT and PANSS during 
hospitalization (D-PANSS), between 3.month PANSS, 6.month 
PANSS and 6.month BPRS scores, a statistically significant negative 
correlation was found (respectively; p = 0.03, p = 0.0001, p = 0.0001, 
p = 0.001) (Table 4). 
Discussion 
Among the somatic treatments used in the practice of psychiatry, only 
ECT is started and stopped within a period of three or four weeks3. 
This situation has led to the occurrence of frequent relapses after ECT. 
Besides the use of ECT in the treatment of acute attacks, initiation of 
preventive treatment may be an appropriate approach in preventing 
relapses. One of the recommended approaches to reduce the rate of 
recurrence is to switch to protective pharmacotherapy following the 
termination of ECT23. However, it has been reported that protective 
pharmacotherapy did not provide an reasonable level of success in 
preventing recurrence23. Another strategy to prevent relapse after 
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psychotic disorders were high in a+cECT+AP group, and it supports 
that the maintenance ECT has been an appropriate approach for this 
patient group25. Lately, Continuation and Maintenance ECT became a 
choice of treatment option for a group of treatment-resistant patients 
who do not benefit much from other treatment options26. 
According to another result of this study; when three groups 
were compared in terms of 1.month-3.month-6.month PANSS and 
BPRS scores; 3.month-6.month PANSS scores of a+cECT+AP group 
were significantly lower than other groups, 1.month-BPRS scores 
of a+cECT+AP group were significantly higher than other groups. 
6.month-BPRS scores of a+cECT+AP group were significantly 
lower than Only AP group. There were no significant differences 
between 1.month-PANSS and 3.month-BPRS scores of the three 
groups. According to several studies, especially in patients with 
treatment-resistant schizophrenia, ECT combined with pharma-
cotherapy is more effective than just pharmacotherapy during the 
acute period21-23. However, for this advantage to be permanent, ECT 
implementation in intervals has been recommended, and mainte-
nance ECT has been raised. Maintenance ECT has been reported 
to be a trustworthy option if drug therapy remains deficient in 
various situations, such as discontinuation, metabolic side effects, 
efficacy strength, duration of remission, and cost-effectiveness26. In 
a study on the use of maintenance ECT in schizophrenia; ECT and 
AP combination have been found to be superior than ECT alone 
or AP treatment alone in terms of preventing relapse19. In another 
study, 11 schizophrenia patients who received ECT during acute 
treatment and who did not receive neuroleptic drugs were applied 
continuation ECT after discharge for a period of six months – 1st 
month weekly, twice a week for two months, once in a month respec-
tively. No deterioration was reported in 8 patients who completed 
the course20. In a case series, schizophrenia patients who do not 
respond to AP drug treatment were followed-up for a year after 
maintenance ECT, and it was reported that remission sustained only 
with chlorpromazine. According to these cases, it has been suggested 
that ECT either changes the course of the disease or increases the 
response to AP27. In this study, 3.month-6.month PANSS scores of 
a+cECT+AP group were lower than other groups, and that result 
supports the effectiveness of continuation ECT in preventing relapse 
and in sustaining remission. Additionally, 1.month-BPRS scores of 
a+cECT+AP group were significantly higher than other groups, and 
this might be related to the resistance of the patients who received 
maintenance ECT. Considering the literature, the maintenance ECT 
patients typically seem to be resistant to pharmacotherapy19,20,26. 
In a study, however, in terms of response to maintenance ECT in 
schizophrenia, good prognosis indicators are acute onset of the 
disease; less admission history; high education level; short-term use 
of the AP; less severe disease; better response to maintenance ECT 
and maintained memory functions. These results suggest that many 
factors need to be assessed when deciding on maintenance ECT28. 
Additionally in this study, decrease in 6th month’s BPRS scores sup-
ports the efficacy of continuation ECT. Finally, in aECT+AP group 
and a+cECT+AP group, significant negative correlation between 
the number of ECT and PANSS rate of change (PANSS-D) and 
3.month-PANSS, 6.month-PANSS, 6.month-BPRS scores suggest 
that the number of ECTs applied is associated with the maintenance 
of remission. Also, preventive ECT consisting of ECT applications 
after 6 months can be considered in patients with recurrent disease, 
responding to acute ECT, and accommodating maintenance ECT29. 
However, these results are required to be supported by further stud-
ies with larger patient groups. Additionally, it is probable that the 
promising outcome of cases in the continuation ECT group was a 
consequence of their more direct contact with medical staff. Patients 
in continuation ECT group were needed to see their clinicians at 
least twice a month to continue treatment. This close contact may 
have served as psychosocial support for the continuation ECT group.
Although this study gives relevant results about continuation 
ECT, it has some limitations. First this was a naturalistic, retrospec-
tively designed study. Assignment of patients to treatment groups 
was not random, and assessments of outcome were not blind, but 
diagnostic and clinical data were all derived from structured instru-
ments. The sample size was modest, possibly resulting in limited 
power to detect significant differences in the clinical characteristics 
of the groups. Another limitation of the study is the probable unre-
ported medical characteristics of these patients that can influence 
the outcome such as use of clozapine, or refractoriness. Therefore, 
the results must be taken with caution as we can not clearly exclude 
that the difference in the outcomes are caused by a design bias. A 
method to partially control for such bias in future research would be 
the use of propensity score matching to perform group comparisons.
Conclusion
Despite the limitations of the method (retrospective study of medical 
files), this study suggests that, in patients with a diagnosis of schizo-
phrenia who have responded to an acute course of ECT, continua-
tion ECT in combination with antipsychotics is more effective than 
antipsychotics alone in preventing relapse. However, prospective 
longitudinal studies are needed to confirm these findings.
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